Using MRI to Study Prostate Tumors and a New Treatment
Author Information
Author(s): Checkley D, Tessier J J, Kendrew J, Waterton J C, Wedge S R
Primary Institution: AstraZeneca
Hypothesis
Can dynamic contrast-enhanced MRI measure permeability changes in prostate tumors after treatment with ZD6474?
Conclusion
The study found that ZD6474 treatment significantly reduced vascular permeability in prostate tumors, which correlates with tumor growth inhibition.
Supporting Evidence
- ZD6474 treatment led to significant reductions in Ktrans, indicating decreased vascular permeability.
- The magnitude of Ktrans change was dose-related, showing a clear relationship with tumor growth inhibition.
- Dynamic contrast-enhanced MRI provided a non-invasive method to assess treatment effects on tumor vasculature.
- Histogram analysis revealed greater effects on Ktrans in the tumor core compared to the rim.
Takeaway
Researchers used a special type of MRI to see how a new medicine affects blood flow in prostate tumors. They found that the medicine helps make the tumors less leaky.
Methodology
The study used dynamic contrast-enhanced MRI to measure changes in vascular permeability in PC-3 prostate tumors after administering ZD6474.
Potential Biases
Potential bias in the selection of tumor models and treatment dosages.
Limitations
The study was limited to a specific tumor model and may not generalize to all types of tumors.
Participant Demographics
Female Swiss athymic mice, at least 8 weeks old.
Statistical Information
P-Value
0.0005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website